1. Shire Faces Criticism on CEO Pay Policy as Crunch Week Looms

    Shire Faces Criticism on CEO Pay Policy as Crunch Week Looms

    (Reuters) - Shire ( SHP.L ), the $47 billion (£33.1 billion) rare disease drugmaker being stalked by Japan’s Takeda Pharmaceutical ( 4502.T ), faces fresh criticism over its executive pay policy from a leading investor advisory group as a crunch week approaches...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Topics Mentioned

  3. Authors